| 001 | 306178 | ||
| 005 | 20251125112322.0 | ||
| 024 | 7 | _ | |a 10.1007/s00117-025-01531-0 |2 doi |
| 024 | 7 | _ | |a pmid:41222668 |2 pmid |
| 024 | 7 | _ | |a 2731-7048 |2 ISSN |
| 024 | 7 | _ | |a 0033-832X |2 ISSN |
| 024 | 7 | _ | |a 1432-2102 |2 ISSN |
| 024 | 7 | _ | |a 2731-7056 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-02418 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Cantré, Daniel |b 0 |
| 245 | _ | _ | |a Added value of sodium MRI in multiparametric MRI for WHO grade II astrocytoma surveillance during "watchful waiting": initial experience. [Zusätzlicher Nutzen der Natrium-MRT bei multiparametrischer MRT zur Überwachung von WHO Grad II Astrozytomen während beobachtenden Abwartens: erste Erfahrungen] |
| 260 | _ | _ | |a [Berlin] |c 2025 |b Springer Medizin Verlag GmbH |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1764066154_3576553 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #LA:E040# / 2025 Nov;65(Suppl 1):126-132 |
| 520 | _ | _ | |a Unresectable WHO grade II astrocytomas require continuous imaging surveillance. To evaluate whether sodium MRI (23Na-MRI) adds diagnostic value to multiparametric MRI and helps predict progressive disease (PD), patients monitored under a 'watchful waiting' strategy were repeatedly examined.Overall, 18 patients with biopsy-proven WHO grade II astrocytoma (10 female, mean age 42 ± 15 years) were prospectively included after baseline imaging. The imaging protocol comprised morphological MRI (T2 TSE, T2 FLAIR, pre- and post-contrast T1 SE), DSC perfusion MRI (n = 17), and 23Na-MRI (n = 9) at 3 T. At baseline, evaluable 23Na-MRI was available for six patients. The Response Assessment in Neuro-Oncology criteria were used to define PD. Semiquantitative ROI analysis was performed on DSC- and 23Na-MRI. Data were analyzed using the Cox regression model.In 14 patients (78%), PD was found after a mean of 420 ± 354 days. For the endpoint time to progression, univariate Cox regression revealed a hazard ratio (HR) of 1.39 for relative regional cerebral blood volume (rrCBV) in the tumor at baseline, and an HR of 1.29 for relative regional cerebral blood flow (rrCBF) at baseline. The 23Na signal in tumor tissue at baseline, normalized to sodium phantoms, revealed an HR of 0.91.Elevation of rrCBV and rrCBF in the tumor indicates poor prognosis, in line with the literature. 23Na-MRI can be used for WHO grade II astrocytoma surveillance. In some treatment-naïve WHO grade II astrocytomas, an initially high sodium signal seems to be prognostically favorable, contrary to the literature on 23Na-MRI in postoperative aftercare. However, due to the small cohort size with evaluable 23Na-MRI at baseline, evidence is limited. In future, 23Na-MRI may help selecting patients for a 'watchful waiting' strategy. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a 3D radial gradient echo projection imaging sequence |2 Other |
| 650 | _ | 7 | |a Brain tumor |2 Other |
| 650 | _ | 7 | |a DSC perfusion MRI |2 Other |
| 650 | _ | 7 | |a Low grade astrocytoma |2 Other |
| 650 | _ | 7 | |a MRI in oncology |2 Other |
| 700 | 1 | _ | |a Gemescu, Ioan |b 1 |
| 700 | 1 | _ | |a Gerigk, Lars |b 2 |
| 700 | 1 | _ | |a Nagel, Armin M |0 P:(DE-He78)054fd7a5195b75b11fbdc5c360276011 |b 3 |u dkfz |
| 700 | 1 | _ | |a Essig, Marco |b 4 |
| 700 | 1 | _ | |a Langner, Sönke |b 5 |
| 700 | 1 | _ | |a Weber, Marc-Andre |0 P:(DE-He78)5d10a98475a036b2a1ad3c2316d4b3ab |b 6 |e Last author |
| 773 | _ | _ | |a 10.1007/s00117-025-01531-0 |0 PERI:(DE-600)3120921-X |n Suppl. 1 |p 126-132 |t Die Radiologie |v 65 |y 2025 |x 2731-7048 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:306178 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)054fd7a5195b75b11fbdc5c360276011 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)5d10a98475a036b2a1ad3c2316d4b3ab |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-18 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-18 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-18 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-18 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b RADIOLOGIE : 2022 |d 2024-12-18 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-18 |
| 920 | 2 | _ | |0 I:(DE-He78)E040-20160331 |k E040 |l E040 Med. Physik in der Strahlentherapie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E040-20160331 |k E040 |l E040 Med. Physik in der Strahlentherapie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E040-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::